Showing results (1-10 of 134) with videos related to

Sort By:
Pageof 14
Journal of Personalized Medicine|April 30, 2021
Phenotyping Rare CFTR Mutations Reveal Functional Expression Defects Restored by TRIKAFTATMOnofrio Laselva, Maria C Ardelean, Christine E Bear
Biochemical Pharmacology|September 11, 2016
The investigational Cystic Fibrosis drug Trimethylangelicin directly modulates CFTR by stabilizing the first membrane-spanning domainOnofrio Laselva, Steven Molinski, Valeria Casavola, et al.
Molecular Pharmacology|April 6, 2018
Correctors of the Major Cystic Fibrosis Mutant Interact through Membrane-Spanning DomainsOnofrio Laselva, Steven Molinski, Valeria Casavola, et al.
Stem Cell Research|January 10, 2025
Testing organ-specific responses to therapies in tissues differentiated from Cystic Fibrosis patient derived iPSCsAbdelkader Daoud, Sunny Xia, Onofrio Laselva, et al.
FASEB Bioadvances|March 4, 2020
Activity of lumacaftor is not conserved in zebrafish Cftr bearing the major cystic fibrosis-causing mutationOnofrio Laselva, Steven Erwood, Kai Du, et al.
STAR Protocols|April 18, 2022
A protocol for identifying the binding sites of small molecules on the cystic fibrosis transmembrane conductance regulator (CFTR) proteinOnofrio Laselva, Evgeniy V Petrotchenko, C Michael Hamilton, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|December 14, 2019
Functional rescue of c.3846G>A (W1282X) in patient-derived nasal cultures achieved by inhibition of nonsense mediated decay and protein modulators with complementary mechanisms of actionOnofrio Laselva, Paul Dw Eckford, Claire Bartlett, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|August 4, 2020
Emerging preclinical modulators developed for F508del-CFTR have the potential to be effective for ORKAMBI resistant processing mutantsOnofrio Laselva, Claire Bartlett, Alec Popa, et al.
Pageof 14